Table 1.
Demographics and clinical characteristics for control and case cohorts.
| Case (n = 185) | Control (n = 185) | p value | |
|---|---|---|---|
| Age at transplant | 0.6571 | ||
| Mean (SD) | 53.6 (14.0) | 53.0 (14.6) | |
| Male | 0.6752 | ||
| No | 82 (44.3%) | 78 (42.2%) | |
| Yes | 103 (55.7%) | 107 (57.8%) | |
| Diabetes | 0.5962 | ||
| No | 108 (58.4%) | 113 (61.1%) | |
| Yes | 77 (41.6%) | 72 (38.9%) | |
| BMI | 0.4281 | ||
| Mean (SD) | 28.6 (5.9) | 28.1 (5.5) | |
| Txp year | 0.8782 | ||
| 2014 | 31 (16.8%) | 33 (17.8%) | |
| 2015 | 24 (13.0%) | 26 (14.1%) | |
| 2016 | 23 (12.4%) | 18 (9.7%) | |
| 2017 | 26 (14.1%) | 21 (11.4%) | |
| 2018 | 35 (18.9%) | 33 (17.8%) | |
| 2019 | 35 (18.9%) | 44 (23.8%) | |
| 2020 | 11 (5.9%) | 10 (5.4%) | |
| Deceased donor | 0.2022 | ||
| No | 34 (18.4%) | 44 (23.8%) | |
| Yes | 151 (81.6%) | 141 (76.2%) | |
| Induction therapy | 0.9482 | ||
| Basiliximab | 67 (36.2%) | 69 (37.3%) | |
| Alemtuzumab | 104 (56.2%) | 101 (54.6%) | |
| Antithymocyte globulin | 14 (7.6%) | 15 (8.1%) | |
| Steroid avoidance | 0.7462 | ||
| No | 119 (64.3%) | 116 (62.7%) | |
| Yes | 66 (35.7%) | 69 (37.3%) | |
| eGFR at 4 months | 0.9351 | ||
| Mean (SD) | 49.7 (20.1) | 49.5 (19.3) |
The baseline demographics and clinical characteristics for both cohorts, after matching. There were no significant differences between the cohorts. Analysis completed using 1two-sample t-test and 2Pearson's chi-squared test.